Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset
Conclusions We observed that a considerable proportion of patients with type 2 diabetes and CKD were receiving metformin and non dose-adjusted DPP-4 inhibitors. Careful consideration of medication use and dosaging is required in the setting of CKD and type 2 diabetes.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Dialysis | Endocrinology | Fortamet | Insulin | Janumet | Januvia | Metabolic Syndrome | Metformin | Urology & Nephrology